Clinical Trials
9 trialsNCT06119581 2026-05-19
SUNRAY-01
Eli Lilly and Company
Phase 3 Recruiting
NCT05261399 2026-04-06
SAFFRON
AstraZeneca
Phase 3 Active not recruiting
NCT04205812 2026-03-31
POD1UM-304
Incyte Corporation
Phase 3 Active not recruiting
NCT03631199 2026-02-25
CANOPY-1
Novartis
Phase 3 Terminated
NCT04035486 2025-10-10
FLAURA2
AstraZeneca
Phase 3 Active not recruiting
NCT04786964 2025-04-02
CONTERNO
Checkpoint Therapeutics, Inc.
Phase 3 Terminated
NCT02264990 2021-02-26
Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers
AbbVie
Phase 3 Completed
NCT02322281 2019-08-14
TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy
Clovis Oncology, Inc.
Phase 3 Terminated
NCT00035035 2006-07-19
A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.
Eli Lilly and Company
Phase 3 Completed